These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30546768)

  • 1. Successful treatment of congestive heart failure with concomitant administration of tolvaptan to enhance the effects of furosemide.
    Nishizaki Y; Yamagami S; Sesoko M; Yamashita H; Daida H
    J Cardiol Cases; 2013 Nov; 8(5):151-154. PubMed ID: 30546768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Udelson JE; Bilsker M; Hauptman PJ; Sequeira R; Thomas I; O'Brien T; Zimmer C; Orlandi C; Konstam MA
    J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
    Ikeda Y; Inomata T; Kida K; Shibagaki Y; Sato N; Izumi T; Ako J;
    Heart Vessels; 2019 Mar; 34(3):442-451. PubMed ID: 30259172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.
    Costello-Boerrigter LC; Boerrigter G; Cataliotti A; Harty GJ; Burnett JC
    Circ Heart Fail; 2010 May; 3(3):412-9. PubMed ID: 20176717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure.
    Mori T; Ohsaki Y; Oba-Yabana I; Ito S
    Hepatol Res; 2017 Jan; 47(1):11-22. PubMed ID: 26990144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
    Ohara K; Masuda T; Murakami T; Imai T; Yoshizawa H; Nakagawa S; Okada M; Miki A; Myoga A; Sugase T; Sekiguchi C; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
    Nephrology (Carlton); 2019 Sep; 24(9):904-911. PubMed ID: 30578654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of long-term tolvaptan administration for chronic heart failure treatment in Japan.
    Nakao Y; Kawakami H; Saito M; Inoue K; Ikeda S; Yamaguchi O
    J Cardiol; 2022 Mar; 79(3):408-416. PubMed ID: 34799217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M; Sunagawa O; Kinugawa K
    Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial.
    Komiya S; Katsumata M; Ozawa M; Haze T; Kawano R; Ohki Y; Suzuki S; Kobayashi Y; Fujiwara A; Saka S; Tamura K; Hirawa N
    Clin Exp Nephrol; 2022 Sep; 26(9):851-858. PubMed ID: 35471469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure.
    Takimura H; Kurozumi A; Taniguchi R; Tsuzuki I; Tajima E; Yamaguchi Y; Kawano M; Takimura Y; Nishio S; Nakano M; Tsukahara R
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):185-196. PubMed ID: 36739357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure.
    Jujo K; Saito K; Ishida I; Furuki Y; Kim A; Suzuki Y; Sekiguchi H; Yamaguchi J; Ogawa H; Hagiwara N
    ESC Heart Fail; 2016 Sep; 3(3):177-188. PubMed ID: 27818782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.
    Kiuchi S; Ikeda T
    Intern Med; 2019 Feb; 58(4):471-475. PubMed ID: 30210135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　- Results From the K-STAR Study.
    Inomata T; Ikeda Y; Kida K; Shibagaki Y; Sato N; Kumagai Y; Shinagawa H; Ako J; Izumi T;
    Circ J; 2017 Dec; 82(1):159-167. PubMed ID: 28835586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF).
    Ng TMH; Grazette LP; Fong MW; Yoon AJ; Lou M; Kuo A; Upadhyay RY; Han EE; Mehra A; Elkayam U
    ESC Heart Fail; 2020 Aug; 7(4):1927-1934. PubMed ID: 32543020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome.
    Saimiya M; Kaku Y; Nishimura M
    CEN Case Rep; 2021 Nov; 10(4):523-526. PubMed ID: 33904139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.